Background. Neutrophil gelatinase-associated lipocalin (NGAL) protein is a promising biomarker to detect acute kidney injury (AKI). Earlier detection of AKI could facilitate evaluation of novel therapeutic strategies. Methods. Random and 24-h urine samples were prospectively obtained from 125 normal volunteers for analytic validation of a urinary enzyme-linked immunosorbent assay for NGAL. For clinical validation of the test, urine from 363 emergency department patients admitted to the hospital was obtained for NGAL enzyme-linked immunosorbent assay and urinalysis and AKI was determined by the use of Acute Kidney Injury Network (AKIN) criteria. Results. NGAL was stable in urine for 7 days when ambient, 4°C or frozen (−20 or −70°C). The assay was linear between 0.24 and10 000 ng/mL with a limit of quantitation of 0.24 ng/ mL. Intra-and inter-assay precision were excellent (coefficient of variation <5%); however, urinary white blood cells were associated with increased NGAL levels. The 95th percentile reference value for NGAL in females is ≤65.0 and ≤23.4 ng/mL
A B S T R AC T
Background. Neutrophil gelatinase-associated lipocalin (NGAL) protein is a promising biomarker to detect acute kidney injury (AKI). Earlier detection of AKI could facilitate evaluation of novel therapeutic strategies. Methods. Random and 24-h urine samples were prospectively obtained from 125 normal volunteers for analytic validation of a urinary enzyme-linked immunosorbent assay for NGAL. For clinical validation of the test, urine from 363 emergency department patients admitted to the hospital was obtained for NGAL enzyme-linked immunosorbent assay and urinalysis and AKI was determined by the use of Acute Kidney Injury Network (AKIN) criteria. Results. NGAL was stable in urine for 7 days when ambient, 4°C or frozen (−20 or −70°C). The assay was linear between 0.24 and10 000 ng/mL with a limit of quantitation of 0.24 ng/ mL. Intra-and inter-assay precision were excellent (coefficient of variation <5%); however, urinary white blood cells were associated with increased NGAL levels. The 95th percentile reference value for NGAL in females is ≤65.0 and ≤23.4 ng/mL in males. Urinary NGAL levels increased with AKI stage but had only fair sensitivity (65%) and specificity (65%) to differentiate no AKI versus Stages 1, 2 or 3 (area under the curve 0.70). Urinalysis with microscopy was very specific (91%) but not very sensitive (22%) with an area under the curve of 0.57. Conclusions. NGAL can be reliably measured in clinical urine samples, although pyuria is an important potential confounder. In our cohort, increased urinary NGAL was associated with AKI by the AKIN criteria; however, the sensitivity and specificity were only fair, in part because patients with prerenal causes are not excluded by AKIN criteria. Conversely, findings on microscopic urinalysis are very specific for AKI. concentration increases. Early diagnosis of AKI could facilitate early initiation of supportive measures and facilitate trials of novel therapeutic strategies [11] .
One promising biomarker for AKI is neutrophil gelatinaseassociated lipocalin (NGAL) protein [10] [11] [12] [13] , a 25-kDa protein, whose expression is induced in kidney tubular cells during the regenerative process after kidney injury [12] . NGAL is also expressed in other epithelial cells, neutrophils and macrophages, and plasma NGAL is upregulated in several clinical conditions [12] .
Proposed uses of NGAL measurement include predicting AKI after cardiac surgery in adult and pediatric populations [1, 7, 8, [14] [15] [16] [17] [18] , in the intensive care unit following iodinated contrast administration [3] , in the emergency department (ED) [6] and in the intensive care unit [19] . NGAL has also been used to predict the severity of AKI [14] , hospital length of stay [1] , need for dialysis [1] and death in pediatric cardiac surgery patients [1] . However, the subsequent performance of NGAL as a biomarker for AKI has been less than hoped in many other studies, although stratification by patient demographics may improve its utility [20] .
Urinalysis is a simple and widely available tool for evaluating renal disease. The presence of renal epithelial cells, renal epithelial cell casts and granular casts are traditional markers of acute tubular necrosis. In the current study, we compared the relative utility of traditional urinalysis and the emerging biomarker urinary NGAL for early detection of AKI.
M AT E R I A L S A N D M E T H O D S
This study was approved by the Mayo Clinic Institutional Review Board.
Analytic urinary NGAL assay validation
All urine samples were received at room temperature and centrifuged (2000 g × 5 min) within 4 h of arriving at the lab and then frozen at −80°C until assayed. NGAL was measured using rapid ELISA kits from BioPorto Diagnostics as per the manufacturer's recommendations. Standards, controls and samples were thawed, mixed, centrifuged and then plated using an XIRIL Neon 100 robotic pipetting station. Plate washing was accomplished utilizing a Thermo Wellwash AC automated plate washer. Analysis was conducted using a Molecular Devices SPECTRAmax 340PC microplate reader and SoftMax pro software.
We performed a pilot study to investigate the effect of centrifugation on urinary NGAL levels. Fresh urine samples (n = 13) with white blood cell (WBC) counts from 0 to >100 cells per high-powered field (HPF) were split into two aliquots: whole (unspun) and the supernatant after centrifugation at 2000 g for 5 min (spun). NGAL was measured immediately (Day 1) and after the samples were frozen at −80°C for 3 days (Day 3).
To further study the effect of WBCs on urinary NGAL level, waste urine samples with varying quantities of urinary WBCs were studied. These samples were centrifuged (2000 g × 2 min) and the supernatant was split into aliquots maintained at room temperature and 4°C prior to NGAL measurement. The WBC pellets were then washed and centrifuged in phosphate-buffered saline three times (5 mL, pH 7.4) and then resuspended in 2 mL of control waste urine. This urine WBC stock was used to spike the urine supernatant samples to a target level of 50-100 WBCs/HPF as verified using an IRIS iQ200 Sprint imaging system (IRIS Diagnostics, Chatsworth, CA). Urinary NGAL levels were then measured immediately after the addition of WBCs and at 2, 4, 8 and 24 h.
Microscopic urinalysis and other urine testing
All laboratory analyses were performed in the Mayo Clinic Renal Testing Laboratory. Urine chemistries and electrolytes were measured using a Roche chemistry autoanalyzer (Hitachi 912), while pH and osmolality were assessed using a pH meter and PSI osmometer (Tecan). Urinary hemoglobin was analyzed by automated dipstick on the IRIS system. Urinalyses were read by trained laboratory personnel blinded to the protocol. The majority of samples are analyzed unspun using an IRIS imaging system in the Mayo Renal Laboratory workflow. All images are reviewed and verified before results are released. Abnormal samples (total protein >100 mg/dL), samples with a cloudy appearance or samples flagged with casts, abnormal cells (e.g. renal tubular epithelial cells) or dysmorphic red blood cells (RBCs) on the IRIS are selected for manual microscopy. By these criteria, ∼30% of those samples that contain any pathological findings listed above undergo confirmatory manual microscopy performed by centrifuging 12 mL of urine for 5 min at 2000 g, removing the supernatant and resuspending the sediment in the residual urine (500 µL). Twenty-five microlitres of the resuspended sediment was placed on a slide for microscopic review of a minimum of 10 fields. and laboratory and clinical parameters were collected by chart review. Two patients were excluded from the final analysis because they did not have a baseline serum creatinine measured before or during hospitalization that was not already elevated (<1.0 mg/dL) and could not be used to grade AKI.
Determination of AKI AKI was determined by chart review using the established Acute Kidney Injury Network (AKIN) criteria [21] . Only the AKIN criteria based upon serum creatinine were used for this purpose since urine output measurements during hospitalization were not consistently available. The change in creatinine from baseline to highest creatinine level during the first 48 h of medical care (ED or hospitalization) was used to calculate the AKIN stage.
Baseline creatinine was defined as lowest creatinine obtained from review of outpatient lab results within 1 year prior to ED visit. If an outpatient serum creatinine was not available during the year prior to ED visit, the lowest creatinine during hospitalization (if <1.0 mg/dL) was considered baseline. Admission creatinine was defined as the creatinine level at admission to the ED.
Stage 1 AKI was defined as an increase in serum creatinine ≥0.3 mg/dL or ≥150-200% from baseline. Stage 2 AKI was defined as an increase in serum creatinine of >200-300% from baseline. Stage 3 AKI was defined as an increase in creatinine to >300% from baseline or serum creatinine ≥4.0 mg/dL with an acute rise of at least 0.5 mg/dL. Need for dialysis was also considered Stage 3 AKI.
Statistical analysis
To complete a reference value study for urinary NGAL, relationships of the 95th percentile with age and sex were evaluated using quantile regression [22] . Models assessing the effect of age on urinary NGAL up to a cubic polynomial were evaluated. Sex was assessed as an indicator variable (0 = female, 1 = male). Standard errors of the quartile regression parameters were estimated using a bootstrap resampling procedure with replacement by 10 000 replicates, from which a P-value is determined. One-sided (95th percentile) reference values and their confidence intervals (CIs) were estimated using the same quantile regression methods.
Association between clinical variables and AKIN stage was assessed using the Kruskal-Wallis exact test. In addition, score CIs were estimated for sensitivity and specificity of urinary markers for AKIN. Receiver operating characteristic analyses were used to estimate the best cutoff value for discriminating between AKIN Stage 0 and Stages 1-3 and between AKIN Stages 0-1 and Stages 2-3. The Wilcoxon rank-sum test was used to assess the relationship between NGAL and the presence of urinary WBC by AKIN stage. Generalized estimating equations were used to assess the effect of centrifugation (0 = no, 1 = yes), storage (0 = Day 1 versus 1 = Day 3) and WBC content [low (0) <21, high (1) ≥21] on the pilot data. All analyses were performed using SAS software and significance was defined as a P < 0.05.
R E S U LT S
NGAL enzyme-linked immunosorbent assay validation Samples were stable after centrifugation for up to 7 days ambient, 4, −20 or −70°C, with toluene or sodium bicarbonate preservatives and with up to three freeze-thaw cycles. Intraassay precision, determined by using five replicates of low (1.9 ng/mL), medium (7.6 ng/mL) and high (13.0 ng/mL) controls, yielded coefficients of variations (CVs) of 3.7, 6.5 and 3.5%, respectively. Inter-assay precision, determined by surveying low, medium and high controls 20 times over 20 days, yielded CVs of 1.2, 1.8 and 0.9%, respectively. The limit of quantitation (LOQ) was determined using calibration imprecision data over 20 days and was 0.24 ng/mL. Accounting for the final sample volume dilution, 10 mg/mL is the absolute LOQ. The limit of determination, determined as 3 SDs of the signal from a blank, was 0.10 ng/mL. Recovery/linearity experiments were performed by serially diluting a sample and demonstrated good performance from 0.24 to 10 000 ng/mL.
Centrifugation did not significantly impact urinary NGAL values. (Supplemental Table 1 ). However, those with higher WBC levels had higher NGAL values. Since WBCs appeared to be a potential confounder, eight samples with high or low quantities of WBCs were centrifuged and assessed over 24 h at room temperature at 4°C. In these eight samples, urinary NGAL appeared to be higher in samples containing greater quantities of WBCs ( Figure 1 ). NGAL did not significantly increase over time at room temperature or 4°C (data not shown). However, when WBCs were spiked into a low NGAL sample (<10.0 ng/mL), urine NGAL increased immediately (mean 20.0 ng/mL), and the amount of increase appeared to be greater when more WBCs were spiked ( Figure 2 ). There was a slight further increase over 24 h, especially in samples with more WBCs and when stored at room temperature.
F I G U R E 1 : Effect of WBCs on urine NGAL concentrations at baseline. Urinary NGAL appeared to be higher in centrifuged urine samples with higher WBC levels when assayed upon receipt in the laboratory. Urinary NGAL levels did not increase for up to 24 h any of these samples (data not shown).
NGAL reference value study
As illustrated on (Table 1) , the 95th percentile reference value for NGAL was ≤65.0 ng/mL in females and ≤23.4 ng/ mL in males. When normalized for creatinine, the 95th percentile reference value was ≤89.9 ng/g/Cr in females and ≤27.2 ng/g Cr in males. Median 24-h urinary NGAL excretion was greater in females than males whether or not NGAL was normalized for creatinine. The median random urinary NGAL was 27.0 ng/mL (range 0.2-153.9 ng/mL) in females versus 12.5 ng/mL (range 0.0-40.8 ng/mL) for males [P < 0.0001 at the median NGAL (ng/mL) and P < 0.0001 at the 95th percentile NGAL (ng/mL)]. However, random urinary NGAL excretion did not vary by age in either gender (all P ≥ 0.27; not shown).
NGAL clinical validation study
Patients in our study with or without AKI as determined by AKIN criteria did not differ statistically in terms of age, sex or race (Table 2 ). Patients with AKI had slightly higher baseline creatinine levels (1.0, 1.1 and 1.1 versus 0.8 mg/dL, P < 0.01).
Peak and admission creatinine, admission estimated glomerular filtration rate, and need for dialysis were also significantly different among AKIN stage groups (Table 2) , but this was expected since a change in serum creatinine and need for dialysis were both used to determine AKIN stage. Additionally, patients with a higher AKIN score had longer inpatient lengths of stay.
With increasing AKIN stage, urinary NGAL levels (ng/mL) increased significantly from a median of 23.0 ng/mL in patients with no AKI to 153.2 ng/mL in patients with AKIN Stage 3 ( Table 3 ). This trend is also evident when urinary NGAL was standardized to urine creatinine. Therefore, normalizing urinary NGAL to creatinine does not appear to improve performance as a biomarker of AKI.
There were definite trends in urinalysis findings across AKIN category with decreasing pH and osmolality but with increasing total protein ( Table 4 ). On microscopy, the presence of renal epithelial cells, epithelial cell casts and granular casts were all more common in patients with AKI. Additionally, hyaline casts, WBCs, RBCs and fat were more common in patients with AKI.
The sensitivities and specificities of urinary NGAL and a microscopic urinalysis to discriminate no AKI from AKIN Stage 1, 2 or 3 vary greatly (Table 5 ). When using a cutoff of ≥42.7 ng/mL (as determined by receiver operator curves) to discriminate no AKI versus AKIN Stage 1, 2 or 3, urinary NGAL has only fair sensitivity of 64.5% and specificity of 64.5%. By comparison, admission serum creatinine in the ED has a sensitivity and specificity of 84.2 and 77.7%, respectively, for subsequent AKI. Viewed individually, finding a renal epithelial cell, renal epithelial or granular cell cast alone had impressive specificity for AKI (93.0-98.6%), but fairly low sensitivity (6.6-14.5%, Table 5 ). Viewed as a group, when a renal epithelial cell, renal epithelial cell cast or granular cast were present, the sensitivity for discriminating no AKI versus AKIN Stage 1, 2 or 3 was only 22.4%, but the specificity was 91.3%. We similarly looked at discriminating the more severe AKIN Stages 2 or 3 from AKIN Stages 0 or 1 (Table 6 ). Sensitivity for all predictive markers was, in general, slightly better.
Higher levels of urinary NGAL or admission serum creatinine and presence of urinary renal epithelial cells all increased the overall risk of death during the hospitalization, although none were statistically significant (2.96, P = 0.06; 2.55, P = 0.09; 3.13, P = 0.09, respectively, Table 7 ). Presence of renal epithelial cell casts individually or combined with renal epithelial cells and/or granular casts are significantly associated with increased risk of death (8.14, P = 0.01; 4.69, P = 0.008, respectively, Table 7 ). Admission serum creatinine, but not urinary NGAL, was also significantly associated with length of hospital stay (Table 8) .
In this ED patient cohort, urinary NGAL levels were associated with urinary WBC levels (Supplemental Table 2 ). In AKIN Stage 1 through AKIN Stage 3, there was not a statistically significant increase in NGAL if WBCs were present. However, if no AKI was present (based on AKIN criteria), the urinary NGAL level in patients with urinary WBCs was 44.6 ng/mL as compared to 11.1 ng/mL in those patients without urinary WBCs (P < 0.0001). Additionally, the median NGAL level of 44.6 ng/mL in patients without AKI and with urinary F I G U R E 2 : Increased urinary NGAL over time in urine samples spiked with WBC and stored at room temperature. Urine samples with <10 ng/mL NGAL were spiked with varying amounts of WBC and assayed at every 4 h up to 32 h. The AKIN score was based on the change in serum creatinine (mg/dL) to peak. The P-values were determined by using the Kruskal-Wallis test. eGFR, estimated glomerular filtration rate. Median urinary NGAL (ng/mL) and NGAL (µg/g creatinine) level standardized to urine creatinine were stratified according to AKIN score as determined by change in creatinine from baseline. The P-values were determined by using the Kruskal-Wallis test.
WBCs was greater than the cutoff urinary NGAL level determined with receiver operator curves and optimal sensitivity and specificity. In this situation, the association of WBCs and NGAL is unclear because both are markers of AKI and the percentage of persons with pyuria increased by AKIN stage from 58% without AKIN to 92% at AKIN Stage 3. Alternatively, the WBCs could release NGAL into the urine before it is voided by the patient.
Although AKIN criteria are objective, patients with prerenal causes of AKI can still meet AKIN criteria. Since fractional excretion of sodium (FeNa) is often used to detect a prerenal cause of AKI, we stratified patients based upon their FeNa, which was available in a subset of 131 individuals. Table 9 demonstrates a stronger relation between urinary NGAL and AKIN stage in patients with a FeNa >1% compared to those with a FeNa ≤1%. A similar observation was made when patients were stratified by a FeCl >1 versus ≤1%.
Therefore, urinary NGAL might be particularly useful among patients without evidence for a pre-renal cause of their AKI. Figure 3 displays the receiver operator curves for urinary NGAL versus urinary markers. In this figure, a urinary marker for AKI was defined as the presence of a renal epithelial cell, renal epithelial cell cast, granular cell cast or a combination. The area under the curve for NGAL was only fair at 0.70 and for urinary markers it was 0.57 ( primarily due to the low sensitivity of this test).
In order to determine independent predictors of AKI, multivariable models were constructed with AKIN stage (0 and 1 versus 2 and 3) and death during hospitalization as the outcomes and urine NGAL, microscopy ( presence of renal epithelial cells, renal epithelial cell casts or granular casts), age and sex as predictors. Urine NGAL (P = 0.02) and microscopy (P = 0.03) were significant independent predictors of AKIN stage, while only microscopy (P = 0.008) predicted death. 
O R I G I N A L A R T I C L E
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D I S C U S S I O N
Our study adds to the literature regarding NGAL since we have fully validated a urinary enzyme-linked immunosorbent assay, developed a reference range and applied the assay in a clinical study. NGAL was stable and the assay characteristics were favorable. However, our group also found that urinary NGAL appears to be influenced by urinary WBCs. In a rat model, urinary NGAL levels were increased after a urinary tract infection was induced, but the relationship between urinary NGAL and urine WBCs has not been fully elucidated in humans [23] . NGAL has even been proposed as an early biomarker for urinary tract infection in pediatric patients [24] . Indeed, it makes sense that urinary NGAL would be increased in the urine with many WBCs because neutrophils contain NGAL. It is also possible that pyuria reflects renal injury, much like renal epithelial cells or casts. In fact, and quite interestingly, pyuria was more common in patients with AKI (Supplemental Table 2 ). Our in vitro results suggest that once urine reaches the laboratory, NGAL is quite stable regardless of WBC level. However, spiking urine with WBCs causes an immediate albeit slight bump in urinary NGAL concentration, followed by some further increase over 24 h at room temperature ( Figure 2) . Therefore, it is conceivable that WBCs immediately release NGAL urine within the collecting system, and, in part, explain the correlation between WBCs and NGAL level we observed (Supplemental Table 2 ). Freezing of urine with WBCs can also increase NGAL levels (Supplemental Table 1) , perhaps due to cell lysis. This potential confounder may need to be considered when evaluating results. Additional work also needs to be done to fully define the influence of urinary WBCs on urinary NGAL levels since pyuria is very common. Indeed, discrepancies among clinical studies examining the predictive value of NGAL could conceivably be explained by the effect of urinary WBCs on NGAL. Perhaps, different urine processing is needed when the urine contains many WBCs to avoid their influence on urinary NGAL levels. It has also been recently determined that NGAL from WBCs may be dimeric while that derived from renal epithelia cells and indicative is monomeric [25] . Unfortunately, western blot is currently needed to make this distinction. The development of a quantitative test specific for monomeric NGAL could improve its specificity as a test for AKI.
In our cohort of ED patients admitted to the hospital, we found that increasing admission levels of urinary NGAL were associated with an increased risk for the development of higher stages of AKIN. However, we found that the sensitivity and specificity for NGAL to predict AKI was only fair at 64.5% [1, 8] . Therefore, urinary NGAL is a far from perfect test for early prediction of AKI. We have also established a reference range for urinary NGAL that differs between men and women. Our study adds to previous work because we compared NGAL to microscopic urinalysis. Urine microscopy is attractive because it is very inexpensive, readily available and noninvasive. Although the urinalysis is used almost universally, its diagnostic value in AKI has not been thoroughly investigated.
In 2008, Perazella et al. [26] did a prospective observational study with microscopic urine findings and devised a urine scoring system based on the presence of RBCs, WBCs, renal epithelial tubular cells and granular cells and casts. This group found that the odds of a physician acute tubular necrosis diagnosis was greatly increased with a score >2 [26] . Our study provides further evidence that the urinalysis is very helpful when predicting AKI. We found that even the presence of one renal epithelial cell, renal epithelial cell cast or granular cell cast/HPF has a specificity of >90% for the diagnosis of AKI. Another advantage of our study is that the diagnosis of AKI was based on a standard classification system and those reading the urinalysis were completely blinded to the diagnosis of AKI. When applied to this population with only a 7% prevalence of more severe AKI (AKIN 2 or 3) , the low sensitivity and high specificity translate into a low positive predictive value but high negative predictive value that makes a diagnosis of AKI unlikely when renal epithelial cells, renal epithelia cell casts or granular casts are absent, although the majority of patients with these renal findings still will not have AKI (Table 6 ). Therefore, microscopic urinalysis remains a worthwhile test due to its easy availability and low cost. Our findings highlight the need to maintain competency in reading urine microscopy, and to not disregard findings that may seem minor such as the presence of one renal epithelial cell. We realize that the findings on microscopic urinalysis are somewhat operator dependent; therefore, the results of this study may not be generalizable.
While Nickolas et al. [6] demonstrated that a urinary NGAL >85 µg/g had a sensitivity and specificity of 0.90 and 0.995, respectively, in a cohort of ED patients. Wegener et al. [8] showed that a urinary NGAL >18.1 ng/mL demonstrated a sensitivity and specificity of 37.7 and 78.1%, respectively, for detecting AKI in patients 3 h following cardiac bypass. The varied performance likely reflects different study designs and patient populations. Importantly, the definition of AKI varies greatly among studies. We used the standardized AKIN criteria, while Nickolas used clinical diagnosis based upon expert review of all cases and excluded cases deemed to be pre-renal. Importantly, patients with pre-renal causes of AKI can achieve AKIN criteria, and NGAL did associate more strongly with AKIN stages when patients were stratified based upon FeNa. Studies also differ when urinary NGAL was measured in respect to potential injury, patient follow-up and baseline patient characteristics [1, 7, 14, 15, 17, [27] [28] [29] . Urinary NGAL is known to be elevated at baseline in patients with underlying renal impairment [30] . Further complicating this issue, urinary NGAL measurement may be influenced by urine storage time, freezing, sample centrifugation and patient gender, which has not been thoroughly investigated. Our study has several limitations. First, there are many inherent problems in using creatinine as a marker of AKI because it is insensitive to minor changes in kidney function and is influenced by hydration status and muscle mass. Unfortunately, there is not a gold standard for diagnosing AKI short of a renal biopsy, which is invasive and impractical in most clinical settings. Because our definition of AKI is less stringent than others used, the performance of NGAL was most likely diminished as compared to other studies. However, it has been shown that even minor elevations in creatinine are associated with increased patient mortality and detecting minor kidney injury is even more difficult [5, 31, 32] Furthermore, we did demonstrate that urinary NGAL was predictive of at least one important clinical outcome, namely death. Our population was also heterogeneous and the timing of the renal insult in our study was not clear. In particular, we excluded patients with baseline chronic kidney disease, as evidenced by an elevated serum creatinine. The issue of time between renal injury and urine sampling may also have had a significant impact on the results since urinary NGAL levels vary greatly depending on the proximity of insult. In studies where NGAL was measured after cardiac bypass surgery, NGAL was elevated for at least 24 h after injury but appeared to peak at ∼6 h after insult [1, 8] . Therefore, if the injury occurred acutely or a long time after ED presentation, the increase in urinary NGAL may have been missed. Lastly, the heterogeneity of our patient population may have altered our results because the baseline levels of urinary NGAL may have been different depending on the patient's baseline renal function and other comorbidities. However, our heterogenous population improves the generalizability of our results. Ideally, more meaningful outcomes than AKI could be studied, especially since AKI does not have a gold standard definition. For example, determining whether NGAL or the microscopic urinalysis predicts future need for renal replacement therapy, chronic kidney disease or death represents important clinical outcomes for future investigation.
In conclusion, increased urinary NGAL modestly predicts subsequent AKI in a non-selected population of patients seen in the ED. Performance of NGAL can be improved if patients with pre-renal causes of AKI are excluded. Abnormal urine microscopy is a very specific but not sensitive marker of AKI. Therefore, an ideal marker of AKI remains to be determined.
However, the predictive value of urinalysis should be appreciated because it is readily available and inexpensive.
S U P P L E M E N TA RY D ATA
Supplementary data are available online at http://ndt.oxfordjournals.org.
AC K N OW L E D G E M E N T S
The authors thank Jakob Eriksen, BioPorto, Inc. for helpful discussions.
CO N F L I C T O F I N T E R E S T S TAT E M E N T
None declared. 
